エピソード

  • Labcorp's Biomarker Testing for Alzheimer Disease
    2024/09/16
    Joseph M. Volpe, MD, Discipline Director, Clinical Neuroscience, Labcorp, discusses biomarker testing for Alzheimer disease and dementia,, including current offerings, reimbursement, and future directions in this evolving area. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    14 分
  • What Neurologists Should Know About End-of-Life Care Discussions
    2024/07/19
    Dan Morhaim, MD, board-certified emergency medicine and internal medicine physician, and former 24-year Maryland State Legislator, highlights the importance of discussing end-of-life care issues with dementia patients and best practices for physicians to follow when broaching this topic. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    21 分
  • Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders
    2024/07/15
    Virginia Man-Yee Lee, PhD, who serves as the John H. Ware 3rd Endowed Professor in Alzheimer's Research at the University of Pennsylvania Perelman School of Medicine, the Director of the Center for Neurodegenerative Disease Research, and Co-Director of the Marian S. Ware Center for Alzheimer's Drug Discovery, presents an overview of tau biomarker testing and research. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    22 分
  • Strategies to Limit ARIA Associated with Alzheimer Disease Treatment
    2024/07/15
    Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    9 分
  • Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab
    2024/07/15
    Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss recent data analyzing the real-world implications of donanemab treatment for people with Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    9 分
  • Emerging Therapeutic Targets for Alzheimer Disease
    2024/07/15
    Howard Fillit, MD, geriatrician, neuroscientist, and Chief Science Officer and Co-Founder of the Alzheimer's Drug Discovery Foundation, discusses the importance of research into new therapeutic targets to develop next-generation treatments for Alzheimer disease, including small molecule compounds. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    14 分
  • Progress in Diagnosis and Management of Neuropsychiatric Symptoms in People Living with Dementia
    2024/07/07
    George Grossberg, MD, Samuel W. Fordyce Professor and Director of Geriatric Psychiatry, Saint Louis University School of Medicine, provides an overview of recent progress in the evaluation, diagnosis, and treatment of neuropsychiatric symptoms in people living with dementia, including nonpharmacologic and pharmacologic interventions. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    13 分
  • How Healthcare Providers Can Partner with Caregivers of People Living with Dementia
    2024/07/07
    Dementia care expert, gerontologist, and author, Laura Wayman provides insights into what caregivers for people living with dementia need from healthcare providers and how clinicians can best partner with caregivers. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    18 分